Table 2.
Dosing regimen and subject characteristics by onabotulinumtoxinA indication.
| Indication | Subjects, n | Gender (M, F), n (%) |
Maximum No. of Treatment Cycles | Mean (SD) No. of Treatment Cycles | Dose Range, U | Mean (SD) Dose, U | Dosing Route |
|---|---|---|---|---|---|---|---|
| Cervical dystonia | 326 | 98 (30), 228 (70) | 15 | 8.4 (3.22) | 20–500 | 187.3 (76.47) | IM |
| Glabellar lines | 846 | 100 (12), 746 (88) | 5 | 2.8 (1.15) | 10–20 | 17.2 (4.51) | IM |
| Hyperhidrosis | 1077 | 439 (41), 638 (59) | 14 | 2.8 (1.97) | 100–150 | 102.8 (11.41) | ID |
| Migraine | 501 | 69 (14), 432 (86) | 3 | 2.8 (0.53) | 75–260 | 165.2 (57.00) | IM |
| Adult post-stroke spasticity | 449 | 224 (50), 225 (50) | 5 | 3.3 (1.42) | 100–600 | 307.3 (79.18) | IM |
| NDO | 619 | 256 (41), 363 (59) | 13 | 3.1 (2.28) | 200–300 | 238.2 (48.59) | IM |
| Lateral canthal lines | 916 | 109 (12), 807 (88) | 4 | 2.5 (1.19) | 24–44 | 33.8 (10.00) | IM |
| Overactive bladder a | 974 | 108, (11), 866 (89) | 13 | 3.6 (2.48) | 20–200 | 108.7 (19.26) | IM |
| Pediatric lower limb spasticity | 325 | 173 (53), 152 (47) | 6 | 4.2 (1.37) | 40–340.5 | 177.7 (76.23) | IM |
| Pediatric NDO | 113 | 65 (58), 48 (42) | 4 | 2.4 (0.92) | 50–200 | 128.4 (59.85) | IM |
| Total | 6146 |
M: 1641 (27),
F: 4505 (73) |
3–15 | 3.3 (2.25) | 10–600 | 134.8 (94.89) | ID, IM |
Indications are ordered by year of onabotulinumtoxinA US Food and Drug Administration approval (see Figure 1 for approval years). Abbreviations—F, female; ID, intradermal; IM, intramuscular; M, male; and NDO, neurogenic detrusor overactivity. a Excludes neurogenic causes, which are instead included in NDO.